SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

IDENTIFIER (ClinicalTrials.gov): NCT06889493

DRUG/TREATMENT: Nivolumab and Ipilimumab

PHASE: 1

STATUS: Recruiting

SPONSOR: Aman Chauhan, MD

Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors.

Click here to download this transcript >>>

DESCRIPTION:

The purpose of this study is to determine:

1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.

2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.

3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT: 

Aman Chauhan, MD

EMAIL: axc3268@med.miami.edu

PHONE: 305-243-8173